182181-38-0 Usage
General Description
3-Fluoro-4-piperazinylbenzenecarbonitrile is a chemical compound with the molecular formula C11H11FN4. It is a white to off-white crystalline solid that is used in the pharmaceutical industry as an intermediate for the synthesis of various pharmaceutical compounds. 3-Fluoro-4-piperazinylbenzenecarbonitrile contains a piperazine ring and a benzene ring with a fluoro group attached to the 3-position and a cyano group attached to the 4-position of the benzene ring. It is known for its potential as a drug candidate and has been studied for its antipsychotic and analgesic properties. Additionally, it has also been investigated for its potential use in treating depression, anxiety, and other neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 182181-38-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,2,1,8 and 1 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 182181-38:
(8*1)+(7*8)+(6*2)+(5*1)+(4*8)+(3*1)+(2*3)+(1*8)=130
130 % 10 = 0
So 182181-38-0 is a valid CAS Registry Number.
InChI:InChI=1/C11H12FN3/c12-10-7-9(8-13)1-2-11(10)15-5-3-14-4-6-15/h1-2,7,14H,3-6H2
182181-38-0Relevant articles and documents
QUINAZOLINONE COMPOUNDS AND RELATED COMPOUNDS
-
Paragraph 0167, (2021/08/27)
Disclosed are substituted quinazolinone compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions such as those relating to unregulated protein functi
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
-
Page/Page column 57, (2008/06/13)
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.